European Pharmaceutical Review
FEBRUARY 27, 2024
Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pandemic, has been exceptional.” Her previous role in the agency was as Director of Vigilance and Risk Management of Medicines.
European Pharmaceutical Review
AUGUST 23, 2022
The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. PTSD is a potentially chronic condition that disrupts lives and can lead to or exacerbate existing health issues such as depression, anxiety, eating disorders, and suicidal thoughts.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 11, 2024
Self-stigma is also prevalent and hinders individuals from getting tested, starting pre‑exposure prophylaxis (PrEP) (if they’re HIV negative), seeking the lifesaving treatments they need (if they’re HIV positive), and can lead to isolation and depression.
European Pharmaceutical Review
MAY 2, 2023
Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe. 2019 [cited 2023 Apr 4]. 1,2 In the EU, an estimated 2.7
Legacy MEDSearch
AUGUST 25, 2022
Early non-randomized European studies have suggested that this leads to reduced incidence of coronary microvascular obstruction (MVO) [3,4] and smaller infarct size, which are both strongly correlated to improvement in heart failure hospitalizations and reduced mortality following primary PCI [5]. About Miracor Medical.
Pharmaceutical Technology
FEBRUARY 8, 2023
Blank acknowledged that in many cases, an exclusively paediatric patient population could lead to difficulties with drawing consent for early phase trials. Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks.
European Pharmaceutical Review
DECEMBER 11, 2023
Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities. Research advances are also helping us learn more about how RNA is processed, potentially leading to new strategies to alter dysfunctional RNA. 2019 ;42:385-406.
Expert insights. Personalized for you.
94 
Let's personalize your content